ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Bioxytran, Inc.
0.0350
-0.0012
-3.31%
成交量:
25.79萬
成交額:
9,030.43
市值:
346.86萬
市盈率:
-1.46
高:
0.0375
開:
0.0363
低:
0.0310
收:
0.0362
52周最高:
0.2283
52周最低:
0.0262
股本:
9,910.39萬
流通股本:
9,860.39萬
量比:
0.35
換手率:
0.26%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.0239
每股收益(LYR):
-0.0379
淨資產收益率:
--
總資產收益率:
-687.83%
市淨率:
-1.18
市盈率(LYR):
-0.92
資料載入中...
總覽
公司
新聞資訊
公告
Bioxytran宣佈Prolectin-M劑量優化取得積極成果,向三期註冊試驗邁進
美股速递
·
03/05
Bioxytran Inc公布SEC文件:試驗期間未報告嚴重不良事件,無治療相關中止案例
美股速递
·
03/02
Bioxytran公司公布廣譜抗病毒藥物Prolectin-M針對輕中度新冠患者的1B/2a期臨床研究積極結果
美股速递
·
03/02
Bioxytran公布積極二期結果:Prolectin-Mbioxytran實現快速病毒清除
美股速递
·
02/11
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BIXT/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BIXT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIXT\",,,,,undefined,":{"symbol":"BIXT","market":"US","secType":"STK","nameCN":"Bioxytran, Inc.","latestPrice":0.035,"timestamp":1774021537832,"preClose":0.0362,"halted":0,"volume":257870,"delay":15,"changeRate":-0.033149171270718224,"floatShares":98603900,"shares":99103900,"eps":-0.0239,"marketStatus":"交易中","change":-0.0012,"latestTime":"03-20 11:45:37 EDT 延時","open":0.0363,"high":0.0375,"low":0.031,"amount":9030.428349999998,"amplitude":0.179558,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.0239,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.0362,"volumeRatio":0.35266},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIXT\",,,,,undefined,":{"symbol":"BIXT","floatShares":98603900,"roa":"-687.83%","roe":"--","lyrEps":-0.037945,"volumeRatio":0.35266,"shares":99103900,"dividePrice":0,"high":0.0375,"amplitude":0.179558,"preClose":0.0362,"low":0.031,"week52Low":0.0262,"pbRate":"-1.18","week52High":0.2283,"institutionHeld":0,"latestPrice":0.035,"eps":-0.0239,"divideRate":0,"volume":257870,"delay":15,"ttmEps":-0.0239,"open":0.0363,"prevYearClose":0.0758,"prevWeekClose":0.0313,"prevMonthClose":0.045,"prevQuarterClose":0.0758,"fiveDayClose":0.0313,"twentyDayClose":0.0449,"sixtyDayClose":0.077},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIXT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIXT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIXT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIXT\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1173660975","title":"Bioxytran宣佈Prolectin-M劑量優化取得積極成果,向三期註冊試驗邁進","url":"https://stock-news.laohu8.com/highlight/detail?id=1173660975","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173660975?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 04:41","pubTimestamp":1772656876,"startTime":"0","endTime":"0","summary":"生物制药公司Bioxytran, Inc.近日宣布,其在研药物Prolectin-M的剂量优化研究取得积极进展。这一关键性突破为推进该药物的三期注册临床试验奠定了重要基础。\n研究数据显示,通过系统化的剂量探索,Prolectin-M在疗效与安全性之间达到了理想平衡。这一成果不仅验证了前期临床数据,更为后续大规模试验的设计提供了科学依据。\n公司计划基于现有数据,加速启动三期临床试验的筹备工作。若后续试验顺利推进,Prolectin-M有望成为针对相关适应症的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0},{"id":"1186486850","title":"Bioxytran Inc公布SEC文件:試驗期間未報告嚴重不良事件,無治療相關中止案例","url":"https://stock-news.laohu8.com/highlight/detail?id=1186486850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186486850?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 22:27","pubTimestamp":1772461635,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会(SEC)的文件显示,生物制药公司Bioxytran, Inc.在其临床研究过程中取得了积极的安全性数据。文件明确指出,该试验未出现任何严重不良事件的报告,同时所有受试者均完成了既定治疗方案,未发生因治疗原因导致的中断情况。\n这一结果凸显了该公司在研疗法的耐受性表现,为后续临床推进提供了关键安全性依据。在当前生物科技领域高度关注药物安全性的背景下,此类数据无疑增强了投资者对研发进程的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIXT"],"gpt_icon":0},{"id":"1175660458","title":"Bioxytran公司公布廣譜抗病毒藥物Prolectin-M針對輕中度新冠患者的1B/2a期臨床研究積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1175660458","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175660458?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 22:26","pubTimestamp":1772461614,"startTime":"0","endTime":"0","summary":"生物制药企业Bioxytran公司近日宣布,其研发的广谱抗病毒药物Prolectin-M在针对轻中度新冠肺炎患者的1B/2a期临床试验中取得突破性进展。该研究数据显示,受试者在用药后病毒载量显著降低,且未出现严重不良反应,标志着这款基于糖工程技术的创新疗法在应对新冠病毒及其他包膜病毒方面展现出巨大潜力。\n研究人员指出,Prolectin-M通过阻断病毒与宿主细胞受体的结合机制发挥作用,这种独特的作用路径使其具备应对多种变异毒株的广谱抗病毒特性。此次临床试验结果将为后续更大规模的二期研究奠定坚实基础,也为全球抗病毒药物研发领域注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0},{"id":"1102628117","title":"Bioxytran公布積極二期結果:Prolectin-Mbioxytran實現快速病毒清除","url":"https://stock-news.laohu8.com/highlight/detail?id=1102628117","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102628117?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 19:02","pubTimestamp":1770807750,"startTime":"0","endTime":"0","summary":"Bioxytran, Inc. (简称Bioxytran) 近日公布了其二期临床试验的积极数据。结果显示,其研发的药物Prolectin-Mbioxytran在试验中展现出能够快速清除病毒的效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}